Spero Therapeutics is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections.
Spero is advancing SPR994, which is designed to be the first broad-spectrum oral antibiotic for use in adults to treat MDR Gram-negative infections.
Spero is also advancing its Potentiator Platform, which it believes will enable it to develop drugs that will expand the spectrum and potency of existing antibiotics, including formerly inactive antibiotics, against Gram-negative bacteria. SPR741, Spero’s lead potentiator product candidate, is a clinical-stage IV-administered agent that has demonstrated in vitro an ability to potentiate over two dozen existing antibiotics by expanding their activity against Gram-negative pathogens.
Copyright Nasdaq. Minimum 15 minutes delayed.
- April 16, 2018 Spero Therapeutics Highlights SPR741 Phase 1 and Preclinical Data at the 28th European Congress of Clinical Microbiology and Infectious Diseases
- April 12, 2018 Spero Therapeutics Appoints Ian A. Critchley, Ph.D., as Head of Clinical Microbiology
- April 02, 2018 Spero Therapeutics Announces Fourth Quarter and Full Year 2017 Operating Results and Provides Pipeline Update